News and press releases

Cancel
  • Hydrogels for tissue engineering

    News / December 15, 2022

    For the development and behavior of cells, their biomechanical environment is as important as biochemical signaling molecules. In the body, biomechanical stimuli are exerted in particular by the extracellular matrix, which provides shape to tissues and surrounds many cell types.

    more info
  • Mitarbeiterin arbeitet im Reinraum (GMP)
    © Fraunhofer IZI

    With the aim of faster, safer and more cost-effective manufacturing of advanced therapy medicinal products (ATMPs), the Department GMP Cell and Gene Therapy of the Fraunhofer Institute for Cell Therapy and Immunology IZI implements a digital Manufacturing Execution System provided by Lonza.

    more info
  • Cell-based immunotherapies, such as CAR T cell therapy, are effective means of treating cancer. However, technological advances in various disciplines are needed to meet the rapidly growing demand for such novel drugs. Researchers from the Fraunhofer Institute for Cell Therapy and Immunology now summarize the current state of research and discuss possible solutions to overcome biological and technical hurdles in their recent article "Potential solutions for manufacture of CAR T cells in cancer immunotherapy" published in the journal Nature Communications.

    more info
  • © REMEDi4ALL

    The EU-funded project REMEDi4ALL willl make a major leap forward in drug repurposing, or finding new therapeutic option for existing drugs, in areas where there are high unmet medical needs. The 3 Fraunhofer institutes participating, for Translational Medicine and Pharmacology ITMP, for Cell Therapy and Immunology IZI and for Algorithms and Scientific Computing SCAI, combine expertise in the realization of in-silico and in-vitro driven drug repurposing programs, the design of predictive in vivo models, the execution of clinical trials and algorithm development for the analysis of drug discovery data.

    more info
  • Application of human umbilical cord mesenchymal stem cells (hUC-MSC's) onto a collagen matrix (Chondro-Gide®)
    © Fraunhofer IZI

    The Fraunhofer Institute for Cell Therapy and Immunology IZI is certified as a GLP test facility. Most recently, the institute conducted, among other things, a preclinical study to test the safety of an ATMP for the treatment of cartilage damage to the knee. An advanced therapy medicinal product (ATMP) developed by BioPlanta GmbH was subjected to extensive testing under GLP conditions with regard to its potential undesirable biodistribution and tumorigenicity.

    more info
  • Doctor hand holds syringe and vaccine
    © Ekaterina_1525 - stock.adobe.com / Fraunhofer IZI / Alernon77 - stock.adobe.com / CoreDESIGN - stock.adobe.com / Fraunhofer IZI

    Coordinated by the Fraunhofer Institute for Cell Therapy and Immunology IZI, seven Fraunhofer institutes are working on the development of automated production technologies for mRNA-based drugs. RNAuto is a Fraunhofer lighthouse project that will receive €8 million in funding from the Fraunhofer-Gesellschaft over the next four years.

    more info
  • The MIC-PreCell Innovation Center at the Fraunhofer Center MEOS will be equipped with state-of-the-art devices for example for high-throughput flow cytometry.
    © Fraunhofer IZI

    At the Fraunhofer Center for Microelectronic and Optical Systems for Biomedicine (MEOS) in Erfurt, the MEOS Innovation Center for Precision Analysis of Cell Therapy Products, or MIC-PreCell for short, is being established until summer 2023. Funded with 750,000 euros from the Free State of Thuringia, this center will then support the development of new analysis methods for quality assurance and process control for the manufacturing of cell-based therapeutic products.

    more info